Beijing Boren Hospital
26
7
7
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
26.9%
7 terminated/withdrawn out of 26 trials
46.2%
-40.3% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma
Role: lead
A Study of BEN301 Injection in the Treatment of Autoimmune Diseases
Role: lead
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
Role: lead
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Role: lead
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Role: lead
Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
Role: lead
Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
Role: lead
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
Role: lead
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children
Role: lead
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
Role: lead
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
Role: lead
Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19
Role: lead
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Role: collaborator
LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma
Role: collaborator
Study of Sequential CAR-T Cell Treating Leukemia Children
Role: lead
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Role: lead
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Role: lead
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
Role: lead
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Role: lead
A Study of CAR-T Cells Targeting Autoimmune Diseases
Role: lead